7.495
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Myriad Genetics (MYGN) Study Shows Reduced Hospitalizations with GeneSight Test | MYGN Stock News - GuruFocus
Myriad Genetics Study Finds GeneSight Test Reduces Psychiatric Hospitalizations in Major Depressive Disorder Patients - Nasdaq
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing | MYGN Stock News - GuruFocus
Myriad Genetics Announces Study Results Show Patients with - GlobeNewswire
New Study: Depression Patients See 40% Drop in Drug Complications with GeneSight Genetic Test - Stock Titan
Demystifying Myriad Genetics: Insights From 10 Analyst Reviews - Benzinga
Pancreatic Cancer Market Growth, Trends & Forecast 2024-2031 | - openPR.com
Myriad Genetics price target lowered to $9 from $11 at BofA - Yahoo Finance
Myriad Genetics (MYGN) Sees Price Target Lowered by BofA Amid Po - GuruFocus
8-DAY DEADLINE ALERT” HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Genetic Screening Testing for Preventive Health Market Top - openPR.com
Myriad Genetics price target lowered to $19 from $27 at Raymond James - MSN
Guggenheim Downgrades Myriad Genetics to Neutral From Buy - marketscreener.com
Myriad Genetics Announces Inducement Awards | MYGN Stock News - GuruFocus
Myriad Genetics Announces Inducement Awards - GlobeNewswire
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Myriad Genetics appoints new CCO to drive growth By Investing.com - Investing.com South Africa
Myriad Genetics appoints new CCO to drive growth - Investing.com Australia
Myriad Genetics Names Brian Donnelly As New Chief Commercial Officer - MarketScreener
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer - GlobeNewswire
Healthcare Tech Leader From Amazon and Illumina Takes Commercial Helm at Myriad Genetics - Stock Titan
Myriad Genetics stock hits 52-week low at $8.44 amid market challenges By Investing.com - Investing.com South Africa
Myriad Genetics stock hits 52-week low at $8.44 amid market challenges - Investing.com
Myriad Genetics, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsMYGN - ACCESS Newswire
10 Analysts Assess Myriad Genetics: What You Need To Know - Benzinga
(MYGN) Technical Data - news.stocktradersdaily.com
Scotiabank cuts Myriad Genetics target to $20, keeps outperform rating By Investing.com - Investing.com Canada
Cancer Biomarkers Market Set to Witness Significant Growth - openPR.com
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now? - MSN
Myriad Genetics stock hits 52-week low at $9.36 amid challenges By Investing.com - Investing.com South Africa
Myriad Genetics stock hits 52-week low at $9.36 amid challenges - Investing.com Australia
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Press Release Service: United States Molecular Diagnostics Market Forecast Report and Company Analysis 2025-2033 Featuring F Hoffmann-la Roche, Illumina, Hologic, Agilent, Qiagen, Myriad Genetics, Abbott, Danaher, BD & CoResearchAndMarkets.co - CRISPR Medicine News
Trend Tracker for (MYGN) - Stock Traders Daily
Global Preventive Healthcare Technologies And Services Market - openPR
The Future of Genetic Testing: Industry Growth, Trends & Key - openPR
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31% - Simply Wall St
Myriad Genetics upgraded at Piper Sandler on balanced risk reward setup - MSN
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade - Benzinga
Myriad Genetics (MYGN) Stock Jumps on Analyst Upgrade - GuruFocus.com
Myriad Genetics Shares Rise After Upgrade From Piper Sandler -March 12, 2025 at 02:53 pm EDT - Marketscreener.com
Myriad Genetics stock upgraded at Piper Sandler (MYGN:NASDAQ) - Seeking Alpha
Why Are Myriad Genetics (MYGN) Shares Soaring Today - Yahoo Finance
This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Medical Equipment Stock Jumps on Upgrade - Schaeffers Research
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):